|
[Check4SPAM] RE: FDA MedWatch- Avastin (bevacizumab) and Sunijtinib Malate- Reports o
[URL Attempt] User received an error - No action required!
low-down Provides auxiliary advice on AVANDIA as a OK and outstanding Treatment privilege for befitting font 2 Diabetes Patients
PHILADELPHIA, July 14, 2008 /PRNewswire-FirstCall/ -- GlaxoSmithKline announces today that the U.S. cialis rezeptfrei kaufen and stimulant authority (FDA) updated the prescribing low-down foor AVANDIA(R) (rosiglitazone maleate) to comprise clinical findings frrom A Diabetes development broadening irritation (accept), a 4- to- 6 year hcairman-to-crumpet examination of AVANDIA versus metformin and glyburide monopsycho in recently diagnosed fount 2 diabetes patients. The proportion of patients with inbarely satisfactory glucose direction at five years was 34 percent with glyburide, 21 percent with metformin and solitary 15 percent with AVANDIA. The imbalance between AVANDIA and the comparators was statistically significant.
|
07-23-2008, 10:19 PM
Linear Mode
